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Abstract. The present study evaluated the association 
between programmed cell death ligand-1 (PD-L1) expression 
and long-term oncologic outcomes in colorectal cancer (CRC). 
PD-L1 expression was evaluated using immunohistochemistry 
in 175 patients who underwent surgical resection for CRC 
between September 1999 and August 2004. Patients were 
grouped according to PD-L1 expression, with 82 (46.9%) 
and 93 (53.1%) in the low and high PD-L1 expression groups, 
respectively. The overall survival (OS) and disease-free 
survival (DFS) rates were significantly better in the high 
expression group compared with in the low expression group 
(OS: 48.2 vs. 32.9%, P=0.047; DFS: 43.3 vs. 32.9%, P=0.021). 
According to the Tumor-Node-Metastasis stage subgroups, the 
OS rates in the low and high expression groups, respectively, 
were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in 
stage II (P=0.789), 19.6 and 51.1% in stage III (P=0.011) and 
9.1 and 0% in stage IV (P=0.005). The DFS rates in the low 
and high expression groups, respectively, were 66.7 and 60.0% 
in stage I (P=0.715), 51.8 and 46.7% in stage II (P=0.857), 
19.6 and 38.3% in stage III (P=0.006) and 9.1 and 0% in 
stage IV (P=0.700). The systemic recurrence rate was signifi-
cantly higher in the low expression group compared with 
in the high expression group (42.7 vs. 12.9%, respectively, 
P=0.030). Low PD‑L1 expression was significantly associated 
with tumor relapse and poor prognosis in stage III CRC.
Introduction
Colorectal cancer (CRC) is one of the most common types 
of cancer in Korea and other developed countries (1,2). The 
carcinogenesis of CRC is driven by genetic and epigenetic 
changes in tumor cells and is also influenced by tumor‑host 
interactions (3-5). Previous studies have reported the potential 
association of molecular markers such as BRAF, KRAS, and 
MMR with prognosis in patients with CRC (6,7). Identification 
of the predictors of poor prognosis and disease recurrence is 
important for the successful treatment of these patients and for 
the discovery of new therapeutic strategies.
Analysis of host immunity against human malignancy is 
increasingly important in cancer research and treatment (8,9). 
Immune checkpoints represent a major defense system of the 
tumor against antitumor immunity in the host and play an 
important role in suppressing the T-cell-mediated immune 
response in the tumor microenvironment (9,10). Programmed 
cell death ligand-1 (PD-L1) expression in tumor cells suppresses 
the cytotoxic activity of CD8-positive T-cells (11-13). 
Up-regulation of PD-L1 has been reported in malignancies 
including lung cancer, esophageal cancer, renal cell carcinoma, 
ovarian cancer, CRC, and breast cancer and may play a central 
role in tumor-immune system interactions (14-19).
PD-L1 expression in tumor cells may be linked to a 
weakened host immune response, resulting in immune escape 
and an adverse prognosis in several malignancies (20-22). 
However, the prognostic role of PD-L1 expression in CRC 
is less clear, with some studies reporting conflicting results 
as to whether PD-L1 expression indicates a better or worse 
prognosis. The prognostic evaluation in these studies has been 
limited because they included patients at various disease stages 
and different study populations (23-27). The aim of this study 
was to evaluate the correlation between PD-L1 expression and 
long-term oncologic outcomes in CRC.
Materials and methods
Patients. Formalin-fixed paraffin-embedded block speci-
mens from surgical resection of the primary tumor were 
obtained from 175 patients with CRC who underwent 
curative surgery and adjuvant chemotherapy at our institu-
tion between September 1999 and August 2004. Baseline 
clinicopathological characteristics and clinical outcome data 
were retrospectively collected from the Colorectal Cancer 
Database of the Department of Colorectal Cancer Surgery 
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and the Pathological Diagnosis Database in the Department of 
Pathology. The study physicians reviewed all medical records 
related to CRC, extracted clinical information including the 
American Joint Committee on Cancer tumor, node, metastases 
(TNM) classification, the numbers of positive and negative 
lymph nodes harvested and tumor location, and determined 
cause of death in deceased individuals.
Production of tissue microarray block. Formalin-fixed, 
paraffin‑embedded tissue samples were produced for tissue 
microarray (TMA). Representative areas of each tumor were 
marked on each hematoxylin and eosin-stained slide and the 
corresponding area of the tissue blocks was sampled. The 
designated area of each donor block was collected using a 
tissue cylinder punch (3 mm diameter), and the samples were 
transferred to a recipient block.
Immunohistochemistry. Sections (4 µm thickness) from 
the TMAs were cut in 10% formalin buffer, embedded in 
paraffin, mounted onto Superfrost Plus glass slides (VWR 
Scientific, West Chester, PA, USA), and incubated at 60˚C 
for 15 min. The slides were deparaffinized in xylene, rehy-
drated in graded alcohol solutions, and washed in tap water. 
Endogenous peroxidase activity was blocked by the addition 
of 3% H2O2. The slides were placed in a steam cooker filled 
with 10 mM sodium citrate buffer (pH 6.0) for antigen retrieval 
after treatment with a blocking agent (DAKO, Carpinteria, 
CA, USA) for 10 min to block nonspecific protein binding. 
Immunohistochemistry for antigen (PD-L1) was performed 
using an autostainer (LV360-2D; LabVision Co., Fremont, 
CA, USA). Reagents and the secondary antibody from the 
commercial LP Kit (TL-125-HD, LabVision Co.) were used 
as provided by the manufacturer. The primary antibody was a 
rabbit polyclonal antibody against PD-L1 (1:400, Anti-PD-L1; 
AnaSpec, Fremont, CA, USA). Immunopositivity was 
evaluated by determining the proportions of positive cells 
(low, ≤50%; and high, >50%).
Evaluation parameters. The sixth edition of the American 
Joint Committee on Cancer (AJCC) classification system 
was used to determine the pathological tumor depth (pT), the 
number of metastasized lymph nodes (pN), and cancer stage. 
A postoperative clinical examination, measurement of serum 
carcinoembryonic antigen CEA levels, chest radiography every 
3 months, and chest/abdominal computed tomography (CT) 
every 6 months were performed during each follow-up exami-
nation over a period of 3 years. After 3 years, the follow-up 
interval was changed to 6 months. Recurrence was defined 
as the presence of radiologically confirmed or histologically 
proven tumor and the location of recurrence was defined as 
the first site of recurrence after complete resection. Local 
recurrence was defined as any tumor recurrence in the surgical 
field; local recurrence with synchronous systemic recurrence 
was included systemic recurrence. The overall survival (OS) 
time was defined as the time from the date of surgery to the 
date of the latest follow-up visit or the date of death due to any 
cause, while the disease‑free survival (DFS) time was defined 
as the time from surgery to any type of recurrence.
Statistical analyses. Data were expressed as medians with 
ranges. Differences in clinicopathological features between 
low and high‑intensity PD‑L1‑positive CRCs were analyzed 
by Chi-square or Fisher's exact tests for categorical variables 
and Student's t-test for continuous variables. Survivals rate 
were determined using the Kaplan-Meier method and log-rank 
tests were used to compare survival rates among subgroups. 
Log-rank tests were also used for univariate analysis and 
independent prognostic factors were identified by multivariate 
analysis using the Cox proportional hazards model to calculate 
hazard ratios. All statistical tests were performed using IBM 
Figure 1. (A) High (52.8%) and (B) low (47.2%) PD-L1 expression.
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SPSS Statistics for Windows, v.21.0 (IBM Corp., Armonk, 
NY, USA). P<0.05 was considered to indicate a statistically 
significant difference.
Ethical statement. The study was approved by the Institutional 
Review Board of Keimyung University and Donsan Medical 
Center (IRB no. 2017-11-037) and performed in accordance 
with the principles of the Declaration of Helsinki. The 
informed consent was waived.
Results
Patient and tumor characteristics. PD-L1 expression was 
categorized as low in 82 (46.9%) patients and high in 93 (53.1%) 
patients (Fig. 1). The patient and tumor characteristics of the 
study cohort stratified by PD‑L1 status are shown in Table I. 
The demographic characteristics were similar between the 
two cohorts for age, sex, preoperative carcinoembryonic 
antigen level, tumor stage, nodal stage, TNM stage, histology, 
lymphovascular invasion, and perinodal extension. There 
was a trend in tumors to be located in the right-sided colon, 
although without statistical significance, in the high PD‑L1 
expression group compared to the low PD-L1 expression 
group (22.6 vs. 12.2%, P=0.073).
Oncologic outcomes and recurrence pattern according to 
PD‑L1 expression. During the median follow-up period of 
88 months (range 1-196 months), the total numbers of deaths 
Table I. Characteristics of patients with CRC according to programmed death-ligand 1 status.
Characteristics Low expression (N=82)  High expression (N=93) P-value
Age (years), median (range)  67 (32-86) 70 (39-100) 0.310
Sex, n (%)   0.711
  Male 48 (58.5) 57 (61.3) 
  Female 34 (41.5) 36 (38.7) 
Preoperative CEA (ng/ml), median (range) 2.82 (0.3-416.8) 3.50 (0.1-332.8) 0.762
Tumor location, n (%)   0.073
  Right side 10 (12.2) 21 (22.6) 
  Left side 72 (87.8) 72 (77.4) 
Tumor stage, n (%)   0.325
  T1 0 (0)  2 (2.2) 
  T2 11 (13.4) 18 (19.4) 
  T3 64 (78.0) 68 (73.1) 
  T4 7 (8.5) 5 (5.4) 
Nodal stage, n (%)   0.109
  N0 36 (43.9) 46 (49.5) 
  N1 20 (24.4) 30 (32.3) 
  N2 26 (31.7) 17 (18.3) 
TNM stage, n (%)   0.100
  Stage I 6 (7.3) 15 (16.1) 
  Stage II 30 (36.6) 30 (32.3) 
  Stage III 35 (42.7) 43 (46.2) 
  Stage IV 11 (13.4) 5 (5.4) 
Histology, n (%)   0.184
  Well-differentiated 4 (4.9) 4 (4.3) 
  Moderately differentiated 67 (81.3) 84 (90.3) 
  Poorly differentiated 8 (9.8) 2 (2.2) 
  Mucinous 3 (3.7) 3 (3.2) 
Lymphovascular invasion, n (%) 61 (74.4) 64 (68.8) 0.415
Perinodal extension, n (%) 15 (18.3) 10 (10.8) 0.155
Recurrence pattern, n (%)   0.199
  Local recurrence 7 (18.4) 7 (38.9) 
  Systemic recurrence 28 (73.7) 9 (50.0) 
  Local and systemic recurrence 3 (7.9) 2 (8.9) 
CRC, colorectal cancer; CEA, carcinoembryonic antigen; TNM, tumor-node-metastasis.
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Figure 2. Ten‑year overall and disease‑free survival of patients with CRC according to PD‑L1 expression. The 10‑year OS and DFS rates were significantly 
higher in the high PD‑L1 expression group than in the low PD‑L1 expression group and low PD‑L1 expression was significantly associated with tumor relapse 
and poor prognosis in stage III CRC. CRC, colorectal cancer.
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and relapse events were 102 and 57, respectively. The 10-year 
OS and DFS rates were significantly higher in the high PD‑L1 
expression group than in the low PD-L1 expression group 
(OS: 48.2 vs. 32.9%, P=0.047; DFS: 43.3 vs. 32.9%, P=0.021) 
(Fig. 2). According to the TNM stage subgroups, the OS rates 
in the low and high PD-L1 expression groups, respectively, 
were 66.7 and 60.0% in stage I (P=0.715), 51.8 and 46.7% in 
stage II (P=0.789), 19.6 and 51.1% in stage III (P=0.011), and 
9.1 and 0% in stage IV (P=0.005). The DFS rates in the low 
and high PD-L1 expression groups, respectively, were 66.7 
and 60.0% in stage I (P=0.715), 51.8 and 46.7% in stage II 
(P=0.857), 19.6 and 38.3% stage III (P=0.006), and 9.1 and 
0% in stage IV (P=0.700). The numbers of involved organs in 
recurrence did not differ between groups (P=0.418; Table II). 
The local recurrence rate was 6.1% in the low PD-L1 expres-
sion group and 7.5% in the high PD-L1 expression group. The 
sites of local recurrence in the low and high PD-L1 expression 
groups included the anastomotic site (1.2 vs. 2.2%, P=0.636), 
perirectum (6.1 vs. 6.5%, P=0.923), and pelvic cavity (3.7 vs. 
1.1%, P=0.254). The systemic recurrence rate was signifi-
cantly higher in the low PD-L1 expression group than in the 
high PD-L1 expression group (42.7 vs. 12.9%, respectively, 
P=0.030). The sites of systemic recurrence most commonly 
affected in the low and high PD-L1 expression groups included 
the liver (25.6 vs. 7.5%, P=0.001), followed by the lungs (6.1 vs. 
3.2%, P=0.364), peritoneum (3.7 vs., 2.2%, P=0.550), extrare-
gional lymph nodes (3.7 vs. 2.2%, P=0.550), abdominal wall 
(1.2 vs. 0%, P=0.286), adrenal glands (1.2 vs. 0%, P=0.286), 
ureters (1.2 vs. 0%, P=0.286), ovaries (1.2 vs. 0%, P=0.286), 
and supraclavicular lymph nodes (1.2 vs. 0%, P=0.286).
Univariate and multivariate survival analyses of 
prognostic factors. Univariate analyses revealed that T-stage 
(P=0.005 and P=0.004, respectively), N-stage (P=0.001 
and P<0.001, respectively), tumor differentiation (P=0.011 
and P=0.014, respectively), lymphovascular invasion (P=0.005 
and P=0.006, respectively), PD-L1 expression (P=0.047 and 
P=0.021, respectively), and perinodal extension (P<0.001 and 
P<0.001, respectively) were significantly associated with OS 
and DFS (Table III) (Fig. 3). Multivariate analysis found that 
T‑stage [hazard ratio (HR), 1.888; 95% confidence interval 
[CI], 1.022-3.488, P=0.042] and perinodal extension (HR, 
2.927; 95% CI, 1.693-5.060, P<0.001) were independent prog-
nostic factors for OS and PD-L1 expression (HR, 1.586; 95% 
CI, 1.069-2.353, P=0.022), while T-stage (HR, 1.903; 95% CI, 
1.033-3.508, P=0.039) and perinodal extension (HR, 3.057; 
95% CI, 1.776-5.259, P<0.001) were independent prognostic 
factors for DFS (Table IV).
Discussion
PD-L1 expression has been reported in tumor cells or 
tumor-infiltrating immune cells in several malignan-
cies, including CRC, and may play a central role in 
immune-oncologic interactions (19,28,29). The present study 
examined the effects of PD-L1 expression on long-term onco-
logic outcomes and recurrence patterns among patients with 
CRC. We found that PD‑L1 expression was significantly asso-
ciated with tumor recurrence and poor prognosis and was an 
independent prognostic factor for DFS, especially in stage III 
CRC. Moreover, the systemic recurrence rate was significantly 
Table II. Recurrence patterns according to programmed death-ligand 1 expression.
Variables Low expression (N=82) High expression (N=93) P-value
Nο. of involved organs      0.418
  1 35 (42.7) 15 (16.1) 
  2 4 (4.9) 4 (4.3) 
  3 1 (1.2) 0 (0) 
Recurrence pattern   0.030
  Local recurrence 5 (6.1) 7 (7.5) 
    Anastomotic site 1 (1.2) 2 (2.2) 0.636
    Perirectum 5 (6.1) 6 (6.5) 0.923
    Pelvic cavity 3 (3.7)  1 (1.1) 0.254
Systemic recurrence 35 (42.7) 12 (12.9) 
  Liver 21 (25.6) 7 (7.5) 0.001
  Lung  5 (6.1) 3 (3.2) 0.364
  Peritoneum 3 (3.7)  2 (2.2) 0.550
  Extraregional lymph nodea 3 (3.7) 2 (2.2) 0.550
  Abdominal wall 1 (1.2) 0 (0) 0.286
  Adrenal gland 1 (1.2) 0 (0) 0.286
  Ureter 1 (1.2) 0 (0) 0.286
  Ovary  1 (1.2) 0 (0) 0.286
  Supraclavicular lymph node 1 (1.2) 0 (0) 0.286
aThe extraregional lymph node includes the para-aortic and lateral pelvic lymph node.
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Figure 3. Ten‑year overall and disease‑free survival of patients with CRC according to prognostic variables with statistical significance. Univariate analyses 
revealed that T‑stage, N‑stage, tumor differentiation, lymphovascular invasion, PD‑L1 expression, and perinodal extension were significantly associated with 
overall and disease-free survival. CRC, colorectal cancer.
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higher and hepatic recurrence was more common in the low 
group than in the high expression group.
Previous studies have reported conflicting results as to 
whether PD-L1 expression indicates a better or worse prog-
nosis in CRC, possibly due to differences in study populations 
and designs (21,23,30). In the present study, the prognostic 
impact of PD-L1 expression on long-term oncologic outcomes 
in CRC differed according to the TNM stage. In early 
stages, including stages I and II, there was no significant 
between-group difference; however, the long-term oncologic 
outcomes of patients with stage III disease was significantly 
better in the high PD-L1 expression group. In this context, our 
results underscore the specificities of tumor immune system 
interactions and microenvironments in CRC according to 
disease stage.
Our evaluation of the recurrence patterns according to 
the PD‑L1 expression status revealed a significantly higher 
systemic recurrence rate in the low PD-L1 expression group 
than that in the high PD-L1 expression group. Moreover, low 
PD‑L1 expression was significantly associated with hepatic 
recurrence. The high systemic recurrence rate and signifi-
cant association with hepatic recurrence in the low PD-L1 
expression group may be reflected in the poor prognosis.
CRC with MMR defects shows high microsatellite 
instability (MSI) and accounts for 12 to 15% of colorectal 
carcinomas. These tumors are infiltrated by higher numbers 
of lymphocytes and are characterized by a more favorable 
prognosis compared to those in MMR-proficient tumors. 
Some studies have reported different impacts of PD-L1 
expression on survival according to microsatellite status. 
Dunne et al (26) demonstrated that PD-L1 expression was 
associated with a significantly worse recurrence‑free survival 
in mismatch‑repair‑deficient tumors, whereas PD‑L1 expres-
sion did not show a statistically significant association with 
recurrence-free survival in mismatch-repair-proficient 
tumors. In contrast, Droeser et al (23) reported that high 
PD‑L1 expression  in mismatch‑repair‑proficient CRC was 
associated with early tumor stage, absence of lymph node 
metastases, lower tumor grade, absence of vascular inva-
sion, high numbers of tumor‑infiltrating CD8+ T cells, and 
Table III. Prognostic factors of survival in univariate analysis.
Prognostic factor No. (n=175) OS (%) P-value DFS (%) P-value
Age (years)   0.554  0.466
  ≤60  47  48.9    48.9 
  >60  128  38.0    33.8 
Sex   0.173  0.130
  Male 105 37.1  33.1 
  Female 70 46.8  46.8 
Location   0.916  0.747
  Right-sided 31 41.9  41.9 
  Left-sided 144 40.9  37.2 
Tumor stage   0.005  0.004
  T1 and T2 31 59.9  59.8 
  T3 and T4 144 37.0  34.2 
Nodal stage   0.001  <0.001
  N0 82 51.8  51.8 
  N1 and N2 93 31.9  25.5 
Histology   0.011  0.014
  Well and moderately differentiated 159 43.4  40.0 
  Poorly differentiated and mucinous 16 18.8  18.8 
Lymphovascular invasion   0.005  0.006
  No 51 56.8  56.8 
  Yes 124 34.6  31.4 
PD-L1 expression   0.047  0.021
  Low 82 32.9  32.9 
  High 93 48.2  43.3 
Perinodal extension   <0.001  <0.001
  No 150 46.6  43.3 
  Yes 25 12  8 
DFS, disease-free survival; OS, overall survival; PALN, para-aortic lymph node; PreOP CEA, preoperative carcinoembryonic antigen; PD-L1, 
programmed death-ligand 1.
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an improved 5-year survival rate. Unfortunately, we did not 
evaluate the status of germline mutations in MLH1, MSH2, 
MSH6, and PMS2; thus, further studies are needed to assess 
the possible association between MSI status and PD-L1 
expression in tumor cells.
Adjuvant chemotherapy has an established role in patients 
with stage III and high-risk stage II CRC; however, its use 
remains controversial in stage II disease due to its restriction 
to a small subgroup of patients with high-risk prognostic 
factors. Dunne et al (26) used relapse follow‑up data to find 
that patients with high PD‑L1 expression had a significantly 
better outcome than that in patients with low expression in 
the untreated stage III population; however, the correlation 
between survival and high PD-L1 expression was lost in the 
stage III patients treated with adjuvant chemotherapy. They 
suggested that patients with high PD-L1 expression should 
not be administered 5-FU-based adjuvant chemotherapy 
following surgery. However, neither high nor low PD-L1 
expression showed a statistically significant association with 
recurrence-free survival in our study, regardless of adjuvant 
chemotherapy (data not shown).
Our study has several limitations, including the small 
number of patients, its retrospective nature, and the lack of 
investigation of other immune-oncologic biomarkers such as 
MSI status, K-ras and BRAF mutations, and the expression of 
other immune checkpoints in tumor and immune cells. Further 
studies are needed to determine the possible association of 
MSI status with immune checkpoint molecules in tumor and 
immune cells in different stages or statuses.
Analysis of our long-term data indicates that love PD-L1 
expression is significantly associated with tumor relapse and 
poor prognosis in CRC.
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Table IV. Prognostic factors of survival in multivariate analysis.
 Overall survival Disease-free survival
 --------------------------------------------------------------------- --------------------------------------------------------------------
Prognostic factor HR (95% CI) P-value HR (95% CI) P-value
Tumor stage    
  T3 and T4 vs. T1 and T2 1.888 (1.022-3.488) 0.042 1.903 (1.033-3.508) 0.039
Histology    
  Poorly differentiated and mucinous vs. 1.647 (0.906-2.995) 0.102 1.409 (0.768-2.586) 0.268
  well and moderately differentiated
Lymphovascular invasion 1.615 (0.992-2.629) 0.054 1.593 (0.980-2.591) 0.061
Programmed death-ligand 1 expression    
  Low vs. high 1.274 (0.852-1.904) 0.238 1.586 (1.069-2.353) 0.022
Nodal stage    
  Positive vs. ≤ negative  1.306 (0.829‑2.056)  0.249  1.430 (0.912‑2.243)  0.119
Perinodal extension    
  Positive vs. ≤ negative   2.927 (1.693‑5.060)  <0.001  3.057 (1.776‑5.259)  <0.001 
HR, hazard ratio; CI, confidence interval.
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